Annexuzlimab is a humanised IgG1 monoclonal antibody which specifically binds to ANXA1 disrupting its interaction with formyl peptide receptors 1 and 2 (FPR1/2). Annexuzlimab arrests cell cycle progression with cancer cells accumulating in the G1 phase. Annexuzlimab targets secreted ANXA1, preventing FPR1/2 activation and reducing cancer progression. Annexuzlimab can be used for the research of triple negative breast cancer, pancreatic cancer and osteosarcoma [1] [2].
In Vivo, Annexuzlimab (1 mg/kg; i.v.; two doses on day 1 and day 8) inhibits tumour growth in BALB/c mice model of triple-negative breast cancer (with a tumour growth inhibition of 23%)[1].
In Vitro, Annexuzlimab (MDX-124) (2.5-10 μM; 72 h) significantly reduces proliferation in a dose-dependent manner in ANXA1-expressing human cancer cell lines, with 10 μM causing >50% viability reduction in some breast and ovarian cell lines, but has no effect on non-ANXA1-expressing lung cancer cell lines[1]. Annexuzlimab (10-25 μM; 24 h) induces a dose-dependent G1 phase cell cycle arrest, with 25 μM causing the most pronounced effects (33.5% G1 increase in MDA-MB-231, 21.2% in A549, 10.8% in BxPC-3), and does not induce apoptosis[1]. Annexuzlimab (5 μM; 72 h) does not induce apoptosis in MCF-7 breast or Caco-2 colorectal cancer cells[1]. Annexuzlimab incubation of osteosarcoma cell lines significantly inhibits cell growth through dose-dependent cell cycle arrest and also significantly reduces the migration ability of osteosarcoma cell line[2].
References:
[1]. Al-Ali HN, et al. A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo. Oncogene. 2024;43(8):608-614.
[2]. F. Dempsey, et al. 1MDX-124, a novel anti-ANXA1 antibody, has significant anti-cancer activity in preclinical models of osteosarcoma.
In Vivo, Annexuzlimab (1 mg/kg; i.v.; two doses on day 1 and day 8) inhibits tumour growth in BALB/c mice model of triple-negative breast cancer (with a tumour growth inhibition of 23%)[1].
In Vitro, Annexuzlimab (MDX-124) (2.5-10 μM; 72 h) significantly reduces proliferation in a dose-dependent manner in ANXA1-expressing human cancer cell lines, with 10 μM causing >50% viability reduction in some breast and ovarian cell lines, but has no effect on non-ANXA1-expressing lung cancer cell lines[1]. Annexuzlimab (10-25 μM; 24 h) induces a dose-dependent G1 phase cell cycle arrest, with 25 μM causing the most pronounced effects (33.5% G1 increase in MDA-MB-231, 21.2% in A549, 10.8% in BxPC-3), and does not induce apoptosis[1]. Annexuzlimab (5 μM; 72 h) does not induce apoptosis in MCF-7 breast or Caco-2 colorectal cancer cells[1]. Annexuzlimab incubation of osteosarcoma cell lines significantly inhibits cell growth through dose-dependent cell cycle arrest and also significantly reduces the migration ability of osteosarcoma cell line[2].
References:
[1]. Al-Ali HN, et al. A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo. Oncogene. 2024;43(8):608-614.
[2]. F. Dempsey, et al. 1MDX-124, a novel anti-ANXA1 antibody, has significant anti-cancer activity in preclinical models of osteosarcoma.